Patients & Survivors

Join us for our new support group, “Legacy of Hope,” dedicated to caregivers who have lost their loved ones to a brain tumor. We’ve created this group to provide a compassionate and understanding space for …

Glioblastoma (GBM) is one of the most complex, deadly, and treatment-resistant cancers. More than 14,490 Americans are expected to receive a GBM diagnosis in 2023.  It can affect anyone—men, women, and children—regardless of age, background, or lifestyle. GBM does not discriminate based on gender, socioeconomic status, region, age, or political affiliation. Every year, on the third Wednesday of July, GBM Awareness Day is observed to acknowledge the profound impact of this devastating disease and to emphasize the national imperative to advance research, raise awareness, and take action toward finding a cure for glioblastoma.Glioblastoma Awareness Day is a vital opportunity to …

We are thrilled to announce the release of episode 13 of the Rare Enough Podcast, where we have the privilege of hosting Colin Gerner, the CEO and co-founder of StacheStrong. This episode is set to …

Imvax, a national sponsor for Head for the Cure, has made significant strides in cancer research, recently announcing the completion of enrollment in their Phase 2b clinical trial of IGV-001. This milestone, coupled with successful …

Courtney Watson and I embarked on an unforgettable journey to Chicago for our first ASCO (American Society of Clinical Oncology) conference, representing Head for the Cure. Our excitement and anticipation were palpable as we navigated …

We are thrilled to announce the release of episode 13 of the Rare Enough Podcast, where we have the privilege of hosting Colin Gerner, the CEO and co-founder of StacheStrong. This episode is set to …

Are you caring for someone with a brain tumor? Join our next Caregiver Conversations on June 13th with guest, GammaTile! Dr. Gatson will discuss how GammaTile works for operable brain tumors, offering insights and hope. Whether you’re …

Head for the Cure has recently partnered with My DIPG Navigator to introduce a pivotal resource for families and patients battling diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). This initiative promises to …

In the United States, there are approximately 110 million adolescents and young adults aged 15 to 39. Among them, around 208,620 are living with either a primary brain or spinal cord tumor, collectively known as central nervous system (CNS) tumors. Despite their rarity, CNS tumors are the most common form of cancer in this age group and rank as the second leading cause of cancer-related deaths among adolescents and young adults, with the top spot for those aged 15 to 24.Although overall cancer survival rates have been increasing, the same progress hasn’t been seen in adolescents and young adults. Transitioning …

In the realm of oncology, the pursuit of more precise and effective treatments is unceasing. Among the innovative modalities that have emerged, proton therapy stands out as a promising advancement, particularly in the treatment of brain cancer. Distinguished by its ability to deliver targeted radiation while minimizing damage to surrounding healthy tissue, proton therapy offers a distinct advantage over conventional radiation therapy methods.Understanding Proton Therapy: Proton therapy operates on the principle of using proton beams to irradiate cancerous cells. Unlike conventional radiation, which employs photons, proton therapy harnesses charged particles, specifically protons, to penetrate the tumor with precision.